A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effects of sotatercept treatment (plus maximum
tolerated background PAH therapy) versus placebo (plus maximum tolerated background PAH
therapy) on time to first event of all cause death, lung transplantation, or PAH
worsening-related hospitalization of ≥ 24 hours, in participants with WHO FC III or FC IV PAH
at high risk of mortality.